$EYEN
EYENOVIA, INC.

2024 Q2 Form 10-Q Financial Statement

#000141057824000870 Filed on May 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $22.63K $4.993K
YoY Change
Cost Of Revenue $490.4K $4.993K
YoY Change
Gross Profit -$467.7K $0.00
YoY Change
Gross Profit Margin -2067.34% 0.0%
Selling, General & Admin $3.759M $3.835M
YoY Change 19.33% 30.45%
% of Gross Profit
Research & Development $4.597M $4.432M
YoY Change 63.54% 75.72%
% of Gross Profit
Depreciation & Amortization $295.4K $247.7K
YoY Change 137.93% 292.48%
% of Gross Profit
Operating Expenses $11.22M $10.27M
YoY Change 88.24% 88.08%
Operating Profit -$11.69M -$10.27M
YoY Change 96.08% 88.08%
Interest Expense $631.7K $678.7K
YoY Change 13.2% 49.48%
% of Operating Profit
Other Income/Expense, Net $634.6K -$655.3K
YoY Change 431.31% -1023.02%
Pretax Income -$11.05M -$10.92M
YoY Change 77.71% 90.28%
Income Tax
% Of Pretax Income
Net Earnings -$11.05M -$10.92M
YoY Change 77.83% 90.3%
Net Earnings / Revenue -48856.13% -218748.27%
Basic Earnings Per Share -$0.21 -$0.23
Diluted Earnings Per Share -$0.21 -$0.23
COMMON SHARES
Basic Shares Outstanding 53.87M 47.39M
Diluted Shares Outstanding 53.12M 46.61M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.301M $7.976M
YoY Change -86.83% -57.09%
Cash & Equivalents $2.300M $8.000M
Short-Term Investments
Other Short-Term Assets $1.500M $2.373M
YoY Change -68.31% -49.72%
Inventory $3.052M $3.514M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $7.284M $14.45M
YoY Change -68.71% -42.02%
LONG-TERM ASSETS
Property, Plant & Equipment $3.041M $3.156M
YoY Change -17.76% 46.58%
Goodwill
YoY Change
Intangibles $6.123M $6.123M
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.138M $908.6K
YoY Change 341.14% 41.2%
Total Long-Term Assets $11.71M $11.73M
YoY Change 92.93% 167.39%
TOTAL ASSETS
Total Short-Term Assets $7.284M $14.45M
Total Long-Term Assets $11.71M $11.73M
Total Assets $18.99M $26.18M
YoY Change -35.27% -10.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.437M $2.145M
YoY Change 9.44% 53.01%
Accrued Expenses $4.833M $6.143M
YoY Change 177.5% 303.22%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $9.545M $8.155M
YoY Change 907.78% 569.02%
Total Short-Term Liabilities $15.85M $16.46M
YoY Change 289.96% 235.84%
LONG-TERM LIABILITIES
Long-Term Debt $4.532M $6.759M
YoY Change -65.6% -9.4%
Other Long-Term Liabilities $983.8K $1.140M
YoY Change -37.9% 0.55%
Total Long-Term Liabilities $5.516M $7.899M
YoY Change -62.63% -8.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.85M $16.46M
Total Long-Term Liabilities $5.516M $7.899M
Total Liabilities $21.36M $24.36M
YoY Change 13.49% 80.5%
SHAREHOLDERS EQUITY
Retained Earnings -$167.5M -$156.4M
YoY Change 28.66% 26.16%
Common Stock $5.582K $4.738K
YoY Change 46.24% 24.72%
Preferred Stock
YoY Change
Treasury Stock (at cost) $0.00 $2.039M
YoY Change -100.0% -87.18%
Treasury Stock Shares
Shareholders Equity -$2.370M $1.818M
YoY Change
Total Liabilities & Shareholders Equity $18.99M $26.18M
YoY Change -35.27% -10.69%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$11.05M -$10.92M
YoY Change 77.83% 90.3%
Depreciation, Depletion And Amortization $295.4K $247.7K
YoY Change 137.93% 292.48%
Cash From Operating Activities -$8.174M -$9.900M
YoY Change 73.38% 41.43%
INVESTING ACTIVITIES
Capital Expenditures $45.74K $114.1K
YoY Change -96.19% -87.61%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$45.74K -$114.1K
YoY Change -96.44% -86.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.545M 3.133M
YoY Change -49.11% -7.84%
NET CHANGE
Cash From Operating Activities -8.174M -9.900M
Cash From Investing Activities -45.74K -114.1K
Cash From Financing Activities 2.545M 3.133M
Net Change In Cash -5.675M -6.873M
YoY Change 468.52% 56.3%
FREE CASH FLOW
Cash From Operating Activities -$8.174M -$9.900M
Capital Expenditures $45.74K $114.1K
Free Cash Flow -$8.220M -$10.01M
YoY Change 38.95% 26.43%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001682639
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47386349
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45553026
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-38365
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
EYENOVIA, INC.
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-1178401
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
295 Madison Avenue, Suite 2400
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
NEW YORK
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10017
CY2024Q1 dei City Area Code
CityAreaCode
833
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
393-6684
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2024Q1 dei Trading Symbol
TradingSymbol
EYEN
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
53870762
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7976106
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14849057
CY2024Q1 us-gaap Inventory Net
InventoryNet
3513860
CY2023Q4 us-gaap Inventory Net
InventoryNet
109798
CY2024Q1 eyen Deferred Clinical Supply Costs
DeferredClinicalSupplyCosts
846301
CY2023Q4 eyen Deferred Clinical Supply Costs
DeferredClinicalSupplyCosts
4256793
CY2024Q1 eyen License Fee And Expense Reimbursements Receivables
LicenseFeeAndExpenseReimbursementsReceivables
88045
CY2023Q4 eyen License Fee And Expense Reimbursements Receivables
LicenseFeeAndExpenseReimbursementsReceivables
123833
CY2024Q1 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1506
CY2023Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1506
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2025267
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1365731
CY2024Q1 us-gaap Assets Current
AssetsCurrent
14451085
CY2023Q4 us-gaap Assets Current
AssetsCurrent
20706718
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3155710
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3374384
CY2024Q1 eyen Security Deposits
SecurityDeposits
197168
CY2023Q4 eyen Security Deposits
SecurityDeposits
197168
CY2024Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6122945
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2122945
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1538814
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1666718
CY2024Q1 eyen Equipment Deposits
EquipmentDeposits
711441
CY2023Q4 eyen Equipment Deposits
EquipmentDeposits
711441
CY2024Q1 us-gaap Assets
Assets
26177163
CY2023Q4 us-gaap Assets
Assets
28779374
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2145272
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1753172
CY2024Q1 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
828286
CY2023Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1658613
CY2024Q1 eyen Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
4751755
CY2023Q4 eyen Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
287928
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
579585
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
501250
CY2024Q1 eyen Notes Payable Unamortized Discount Current
NotesPayableUnamortizedDiscountCurrent
621712
CY2023Q4 eyen Notes Payable Unamortized Discount Current
NotesPayableUnamortizedDiscountCurrent
503914
CY2024Q1 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
8155025
CY2023Q4 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
5329419
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
16459923
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9530382
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1140231
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1292667
CY2024Q1 eyen Notes Payable Unamortized Discount Noncurrent
NotesPayableUnamortizedDiscountNoncurrent
200711
CY2023Q4 eyen Notes Payable Unamortized Discount Noncurrent
NotesPayableUnamortizedDiscountNoncurrent
448367
CY2024Q1 us-gaap Other Long Term Notes Payable
OtherLongTermNotesPayable
2103456
CY2023Q4 us-gaap Other Long Term Notes Payable
OtherLongTermNotesPayable
4355800
CY2024Q1 eyen Convertible Notes Payable Unamortized Discount Noncurrent
ConvertibleNotesPayableUnamortizedDiscountNoncurrent
344219
CY2023Q4 eyen Convertible Notes Payable Unamortized Discount Noncurrent
ConvertibleNotesPayableUnamortizedDiscountNoncurrent
398569
CY2024Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
4655781
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
4601431
CY2024Q1 us-gaap Liabilities
Liabilities
24359391
CY2023Q4 us-gaap Liabilities
Liabilities
19780280
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
6000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
6000000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47386349
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45553026
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
4738
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4555
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
158226694
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
154486098
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-156413660
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-145491559
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
1817772
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
8999094
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26177163
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28779374
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4993
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
4993
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4431601
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2521950
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3835223
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2936886
CY2024Q1 eyen Reacquisition Of License Rights
ReacquisitionOfLicenseRights
2000000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
10266824
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
5458836
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10266824
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5458836
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-97558
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
70993
CY2024Q1 us-gaap Interest Expense
InterestExpense
678658
CY2023Q1 us-gaap Interest Expense
InterestExpense
454003
CY2024Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
120939
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
102480
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-655277
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-280530
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-10922101
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5739366
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46606790
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46606790
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37410587
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37410587
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
8999094
CY2024Q1 eyen Stock Issued At Market Offering During Period Value New Issues
StockIssuedAtMarketOfferingDuringPeriodValueNewIssues
3194547
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
546232
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-10922101
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
1817772
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
17234565
CY2023Q1 eyen Stock Issued At Market Offering During Period Value New Issues
StockIssuedAtMarketOfferingDuringPeriodValueNewIssues
3499592
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
819064
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5739366
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
15813855
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-10922101
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5739366
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
546232
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
819064
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
247728
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
63119
CY2024Q1 eyen Amortization Of Debt Discount
AmortizationOfDebtDiscount
184207
CY2023Q1 eyen Amortization Of Debt Discount
AmortizationOfDebtDiscount
149490
CY2024Q1 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
85051
CY2024Q1 us-gaap Inventory Write Down
InventoryWriteDown
198034
CY2024Q1 eyen Provision For Settlement Of Defective Clinical Supply
ProvisionForSettlementOfDefectiveClinicalSupply
100000
CY2024Q1 eyen Non Cash Rent Expense
NonCashRentExpense
127904
CY2023Q1 eyen Non Cash Rent Expense
NonCashRentExpense
133907
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
154486
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
212025
CY2024Q1 eyen Increase Decrease In License Fee And Expense Reimbursements Receivables
IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables
-35788
CY2023Q1 eyen Increase Decrease In License Fee And Expense Reimbursements Receivables
IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables
-210109
CY2024Q1 eyen Increase Decrease In Deferred Clinical Supply Costs
IncreaseDecreaseInDeferredClinicalSupplyCosts
-375944
CY2023Q1 eyen Increase Decrease In Deferred Clinical Supply Costs
IncreaseDecreaseInDeferredClinicalSupplyCosts
1067714
CY2024Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
567598
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
392100
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-26207
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-830327
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1110002
CY2024Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
363828
CY2023Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-42933
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-74101
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-136150
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9891747
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6958708
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
114105
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
920865
CY2023Q1 eyen Vendor Deposits For Property Plant And Equipment
VendorDepositsForPropertyPlantAndEquipment
-82813
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-114105
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-838052
CY2024Q1 eyen Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
3293347
CY2023Q1 eyen Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
3607827
CY2024Q1 eyen Payments Of Stock Issuance Costs At Market Offering
PaymentsOfStockIssuanceCostsAtMarketOffering
98800
CY2023Q1 eyen Payments Of Stock Issuance Costs At Market Offering
PaymentsOfStockIssuanceCostsAtMarketOffering
108235
CY2024Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
61646
CY2023Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
100030
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3132901
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3399562
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6872951
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4397198
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14849057
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22863520
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7976106
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18466322
CY2024Q1 us-gaap Interest Paid Capitalized
InterestPaidCapitalized
494451
CY2023Q1 us-gaap Interest Paid Capitalized
InterestPaidCapitalized
304512
CY2024Q1 eyen Purchase Of Insurance Premium Financed By Short Term Note Payable
PurchaseOfInsurancePremiumFinancedByShortTermNotePayable
505050
CY2023Q1 eyen Purchase Of Insurance Premium Financed By Short Term Note Payable
PurchaseOfInsurancePremiumFinancedByShortTermNotePayable
609140
CY2024Q1 eyen Accrual For Intangible Assets Milestone Obligation
AccrualForIntangibleAssetsMilestoneObligation
4000000
CY2024Q1 eyen Reclassification Of Deferred Clinical Supply Costs To Inventories
ReclassificationOfDeferredClinicalSupplyCostsToInventories
3034498
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
350473
CY2023Q1 eyen Cashless Exercise Of Stock Options
CashlessExerciseOfStockOptions
2
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8000000.0
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-156400000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-10900000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5700000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9900000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7000000.0
CY2024Q1 us-gaap Treasury Stock Value
TreasuryStockValue
2039357
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
5450118
CY2024Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
7301681
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
14243870
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-10922101
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5739366
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10922101
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5739366
CY2024Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
46471045
CY2024Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
452218
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
30683
CY2024Q1 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
3061642
CY2023Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
79115
CY2024Q1 us-gaap Inventory Net
InventoryNet
3513860
CY2023Q4 us-gaap Inventory Net
InventoryNet
109798
CY2024Q1 us-gaap Inventory Write Down
InventoryWriteDown
198034
CY2023Q1 us-gaap Inventory Write Down
InventoryWriteDown
0
CY2023Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
37380976
CY2024Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
135745
CY2023Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
29611
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46606790
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37410587
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19383197
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14026269
CY2024Q1 us-gaap Prepaid Insurance
PrepaidInsurance
738752
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
167338
CY2024Q1 eyen Payroll Taxes Receivable
PayrollTaxesReceivable
500512
CY2023Q4 eyen Payroll Taxes Receivable
PayrollTaxesReceivable
500684
CY2024Q1 eyen Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
260489
CY2023Q4 eyen Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
421056
CY2024Q1 eyen Prepaid Conference Expenses Current
PrepaidConferenceExpensesCurrent
191556
CY2023Q4 eyen Prepaid Conference Expenses Current
PrepaidConferenceExpensesCurrent
123556
CY2024Q1 eyen Prepaid General And Administrative Expenses
PrepaidGeneralAndAdministrativeExpenses
213707
CY2023Q4 eyen Prepaid General And Administrative Expenses
PrepaidGeneralAndAdministrativeExpenses
85938
CY2024Q1 eyen Prepaid Patent Expense
PrepaidPatentExpense
73501
CY2023Q4 eyen Prepaid Patent Expense
PrepaidPatentExpense
48409
CY2024Q1 eyen Prepaid Rent And Security Deposit
PrepaidRentAndSecurityDeposit
18750
CY2023Q4 eyen Prepaid Rent And Security Deposit
PrepaidRentAndSecurityDeposit
18750
CY2024Q1 eyen Prepaid Professional Fees Current
PrepaidProfessionalFeesCurrent
28000
CY2023Q4 eyen Prepaid Professional Fees Current
PrepaidProfessionalFeesCurrent
0
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2025267
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1365731
CY2024Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
406215
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1302997
CY2024Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
422071
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
355616
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
828286
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1658613
CY2024Q1 eyen Accrued Intangible Asset Milestone Obligation
AccruedIntangibleAssetMilestoneObligation
4000000
CY2024Q1 eyen Accrued Settlement On Defective Clinical Supply
AccruedSettlementOnDefectiveClinicalSupply
500000
CY2023Q4 eyen Accrued Settlement On Defective Clinical Supply
AccruedSettlementOnDefectiveClinicalSupply
100000
CY2024Q1 eyen Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
116388
CY2023Q4 eyen Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
89872
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
113479
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
63028
CY2024Q1 eyen Credit Card Payable
CreditCardPayable
16789
CY2023Q4 eyen Credit Card Payable
CreditCardPayable
27193
CY2024Q1 eyen Accrued Franchise Tax
AccruedFranchiseTax
5000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
99
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7835
CY2024Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
4751755
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
287928
CY2024Q1 eyen Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
3200000
CY2024Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1833323
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
546232
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
819064
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y1M6D
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.33
CY2024Q1 us-gaap Notes Payable Current
NotesPayableCurrent
8776737
CY2024Q1 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
621712
CY2024Q1 eyen Notes Payable Current Net Of Debt Discount Current Current Portion
NotesPayableCurrentNetOfDebtDiscountCurrentCurrentPortion
8155025
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
5833333
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
503914
CY2023Q4 eyen Notes Payable Current Net Of Debt Discount Current Current Portion
NotesPayableCurrentNetOfDebtDiscountCurrentCurrentPortion
5329419
CY2024Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
7304167
CY2024Q1 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
544930
CY2024Q1 eyen Notes Payable Non Current Net Of Debt Discount Non Current Non Current Portion
NotesPayableNonCurrentNetOfDebtDiscountNonCurrentNonCurrentPortion
6759237
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
9804167
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
846936
CY2023Q4 eyen Notes Payable Non Current Net Of Debt Discount Non Current Non Current Portion
NotesPayableNonCurrentNetOfDebtDiscountNonCurrentNonCurrentPortion
8957231
CY2020Q4 eyen Written Notice Period For Termination Of Agreement
WrittenNoticePeriodForTerminationOfAgreement
P90D
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
74101
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
136150
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
350473
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y9M21D
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.100
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.100
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
542718
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
675400
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
560996
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
214619
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1993733
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
273917
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1719816
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
579585
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1140231
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
106019
CY2023Q4 eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Non Vested Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice
2.12
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
106019
CY2024Q1 eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Non Vested Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice
2.12
CY2024Q1 eyen Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Rs Us Undelivered Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRSUsUndeliveredNumber
135745
CY2024Q1 eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested Rs Us Undelivered Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedRSUsUndeliveredWeightedAverageExercisePrice
2.22
CY2024Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
6022877
CY2024Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P5Y9M18D
CY2024Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
4147529
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2407571
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.61
CY2019Q2 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1
CY2019Q2 us-gaap Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage
DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
0.04
CY2024Q1 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
102483
CY2023Q1 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
78969
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001410578-24-000870-index-headers.html Edgar Link pending
0001410578-24-000870-index.html Edgar Link pending
0001410578-24-000870.txt Edgar Link pending
0001410578-24-000870-xbrl.zip Edgar Link pending
eyen-20240331.xsd Edgar Link pending
eyen-20240331x10q.htm Edgar Link pending
eyen-20240331xex10d1.htm Edgar Link pending
eyen-20240331xex31d1.htm Edgar Link pending
eyen-20240331xex31d2.htm Edgar Link pending
eyen-20240331xex32d1.htm Edgar Link pending
eyen-20240331xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
eyen-20240331_def.xml Edgar Link unprocessable
eyen-20240331_lab.xml Edgar Link unprocessable
eyen-20240331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
eyen-20240331x10q_htm.xml Edgar Link completed
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
eyen-20240331_cal.xml Edgar Link unprocessable